TW202042820A - 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法 - Google Patents

以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法 Download PDF

Info

Publication number
TW202042820A
TW202042820A TW109102121A TW109102121A TW202042820A TW 202042820 A TW202042820 A TW 202042820A TW 109102121 A TW109102121 A TW 109102121A TW 109102121 A TW109102121 A TW 109102121A TW 202042820 A TW202042820 A TW 202042820A
Authority
TW
Taiwan
Prior art keywords
individual
months
protein
cytochrome
administered
Prior art date
Application number
TW109102121A
Other languages
English (en)
Chinese (zh)
Inventor
路克 沃可
克里斯托弗 恩德雷斯
安東尼 李
灝 孫
愛薇爾 托普列茲艾瑞克森
Original Assignee
美商西雅圖遺傳學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商西雅圖遺傳學股份有限公司 filed Critical 美商西雅圖遺傳學股份有限公司
Publication of TW202042820A publication Critical patent/TW202042820A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW109102121A 2019-01-28 2020-01-21 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法 TW202042820A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962797854P 2019-01-28 2019-01-28
US62/797,854 2019-01-28

Publications (1)

Publication Number Publication Date
TW202042820A true TW202042820A (zh) 2020-12-01

Family

ID=69740562

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109102121A TW202042820A (zh) 2019-01-28 2020-01-21 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法

Country Status (13)

Country Link
US (1) US20220193076A1 (enExample)
EP (1) EP3917533A1 (enExample)
JP (1) JP2022523045A (enExample)
KR (1) KR20210119498A (enExample)
CN (1) CN113613656A (enExample)
AR (1) AR119681A1 (enExample)
AU (1) AU2020215551A1 (enExample)
CA (1) CA3126279A1 (enExample)
IL (1) IL284850A (enExample)
MX (1) MX2021008834A (enExample)
SG (1) SG11202107488PA (enExample)
TW (1) TW202042820A (enExample)
WO (1) WO2020159822A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7328151B2 (ja) 2017-04-28 2023-08-16 シージェン インコーポレイテッド Ｈｅｒ２陽性がんの処置
US20220125877A1 (en) * 2019-07-10 2022-04-28 Sun Yat-Sen University Method for treating colorectal cancer
MX2023003406A (es) * 2020-09-28 2023-03-31 Seagen Inc Metodos de tratamiento de tumores solidos impulsados por alteraciones de her2 con tucatinib en combinacion con un anticuerpo anti-her2.
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
CN117243959A (zh) * 2022-10-13 2023-12-19 山东大学 治疗骨质疏松的方法和药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
WO1993017668A1 (en) 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
JP7328151B2 (ja) * 2017-04-28 2023-08-16 シージェン インコーポレイテッド Ｈｅｒ２陽性がんの処置

Also Published As

Publication number Publication date
WO2020159822A1 (en) 2020-08-06
IL284850A (en) 2021-08-31
EP3917533A1 (en) 2021-12-08
US20220193076A1 (en) 2022-06-23
KR20210119498A (ko) 2021-10-05
AR119681A1 (es) 2022-01-05
AU2020215551A1 (en) 2021-08-05
SG11202107488PA (en) 2021-08-30
MX2021008834A (es) 2021-09-28
JP2022523045A (ja) 2022-04-21
CN113613656A (zh) 2021-11-05
CA3126279A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
US12048698B2 (en) Treatment of HER2 positive cancers
TW202042820A (zh) 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法
TWI649081B (zh) 治療固態腫瘤之方法
US20230310455A1 (en) Combination therapies for treatment of her2 cancer
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
JP2008501006A (ja) Ｓｒｃキナーゼ阻害剤ＡＺＤ０５３０、および、抗エストロゲン剤またはＥＧＦＲ−ＴＫ−阻害剤を含む組み合わせ製品
WO2020192506A1 (zh) 西奥罗尼用于小细胞肺癌的治疗
US12383557B2 (en) Treatment of cancer using combination therapies comprising GDC-6036 and GDC-0077
MX2014012001A (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek.
US20250049807A1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
US20230338347A1 (en) New Use of Inhibitors of the Notch Signalling Pathway
WO2025199434A1 (en) Methods of treating breast cancer using a pyrazole compound
CN120957724A (zh) 索托拉西布/卡铂/培美曲塞在癌症治疗中的剂量方案